Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-08T12:24:48.663Z Has data issue: false hasContentIssue false
  • English
  • Français

Secondary, profound, sensorineural hearing loss after recovery from haemolytic uraemic syndrome due to enterohaemorrhagic Escherichia coli, and subsequent cochlear implantation, in two Japanese children

Published online by Cambridge University Press:  14 February 2013

S B Minami ,
H Takegoshi ,
Y Shinjo  and
K Kaga
S B Minami*
Affiliation:
National Institute of Sensory Organs, National Tokyo Medical Centre, Tokyo, Japan
H Takegoshi
Affiliation:
Department of Otolaryngology, International University of Health and Welfare, Mita Hospital, Tokyo, Japan
Y Shinjo
Affiliation:
National Institute of Sensory Organs, National Tokyo Medical Centre, Tokyo, Japan
K Kaga
Affiliation:
National Institute of Sensory Organs, National Tokyo Medical Centre, Tokyo, Japan Department of Otolaryngology, International University of Health and Welfare, Mita Hospital, Tokyo, Japan
*
Address for correspondence: Dr Shujiro B Minami, 2-5-1 Higashigaoka Meguro-ku, Tokyo 152-8902, Japan Fax: +81 3 3412 9811 E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives:

To describe two cases of profound hearing loss secondary to enterohaemorrhagic Escherichia coli infection, and to report the efficacy of subsequent cochlear implantation.

Results:

The first case was a four-year-old girl admitted to hospital with Escherichia coli O157 infection and haemolytic uraemic syndrome. Mild hearing loss was confirmed five months after discharge, progressing to profound loss three months later. At the age of seven years, she underwent cochlear implantation, with remarkable improvement in speech perception and production. The second case was a three-year-old boy admitted with haemolytic uraemic syndrome caused by Escherichia coli O111 infection. One year after disease onset, profound hearing loss was confirmed. Cochlear implantation at the age of five years produced significant recovery of auditory function.

Conclusion:

This study represents the first published report of secondary hearing loss after recovery from haemolytic uraemic syndrome caused by enterohaemorrhagic Escherichia coli. It indicates that cochlear implantation can restore hearing function in such patients.

Keywords

Escherichia Coli O157Cochlear ImplantsHemolytic-Uremic SyndromeHearing Loss
Type
Clinical Records
Information
The Journal of Laryngology & Otology , Volume 127 , Issue 3 , March 2013 , pp. 306 - 310
Copyright
Copyright © JLO (1984) Limited 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Caprioli, A, Morabito, S, Brugere, H, Oswald, E. Enterohaemorrhagic Escherichia coli: emerging issues on virulence and modes of transmission. Vet Res 2005;36:289–311CrossRefGoogle ScholarPubMed
2Nataro, JP, Kaper, JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998;11:142–201CrossRefGoogle ScholarPubMed
3Pennington, H. Escherichia coli O157. Lancet 2010;376:1428–35CrossRefGoogle ScholarPubMed
4Griffin, PM, Tauxe, RV. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol Rev 1991;13:60–98CrossRefGoogle ScholarPubMed
5Scheiring, J, Andreoli, SP, Zimmerhackl, LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 2008;23:1749–60CrossRefGoogle ScholarPubMed
6Tozzi, AE, Caprioli, A, Minelli, F, Gianviti, A, De Petris, L, Edefonti, A et al. Shiga toxin-producing Escherichia coli infections associated with hemolytic uremic syndrome, Italy, 1988–2000. Emerg Infect Dis 2003;9:106–8CrossRefGoogle ScholarPubMed
7Gerber, A, Karch, H, Allerberger, F, Verweyen, HM, Zimmerhackl, LB. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997–2000, in Germany and Austria: a prospective study. J Infect Dis 2002;186:493–500CrossRefGoogle ScholarPubMed
8Tarr, PI, Gordon, CA, Chandler, WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005;365:1073–86Google ScholarPubMed
9Siegler, R,Oakes, R. Hemolytic uremic syndrome; pathogenesis, treatment, and outcome. Curr Opin Pediatr 2005;17:200–4CrossRefGoogle ScholarPubMed
10Karpman, D, Sartz, L, Johnson, S. Pathophysiology of typical hemolytic uremic syndrome. Semin Thromb Hemost 2010;36:575–85CrossRefGoogle ScholarPubMed
11Sandvig, K. Shiga toxins. Toxicon 2001;39:1629–35CrossRefGoogle ScholarPubMed
12Zheng, XL, Sadler, JE. Pathogenesis of thrombotic microangiopathies. Ann Rev Pathol 2008;3:249–77CrossRefGoogle ScholarPubMed
13Lin, CD, Wei, IH, Tsai, MH, Kao, MC, Lai, CH, Hsu, CJ et al. Changes in guinea pig cochlea after transient cochlear ischemia. Neuroreport 2010;21:968–75CrossRefGoogle ScholarPubMed
14Frank, C, Werber, D, Cramer, JP, Askar, M, Faber, M, An Der Heiden, M et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011;365:1771–80CrossRefGoogle Scholar